Cnbx Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cnbx Pharmaceuticals Inc (CNBK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cnbx Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 9M combined for tracked competitors (6.0% combined share).
- Peer differentiation: Revenue per employee of $0.27M compares with $0.19M for the peer group (1.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Cnbx Pharmaceuticals Inc vs. its Competitors, Q3 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cnbx Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cnbx Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cnbx Pharmaceuticals Inc's competitor groups requires a Commercial License.
Cnbx Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cnbx Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (4) | - | - | - | |
| High-Confidence Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNBK Stock Performance relative to its Competitors
CNBK Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Corbus Pharmaceuticals Holdings Inc | 282.9% | Outperformed |
| 3 | Pharmacyte Biotech Inc | 282.9% | Outperformed |
| 4 | Novabridge Biosciences | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cnbx Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Cnbx Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cnbx Pharmaceuticals Inc | - | 0.54 |
| Corbus Pharmaceuticals Holdings Inc | 132.36 | 1.54 |
| Novabridge Biosciences | 130.72 | - |
| Inmed Pharmaceuticals Inc | 5.66 | 6.97 |
| Pharmacyte Biotech Inc | 4.41 | - |
| SUBTOTAL | 273.15 | 9.05 |
Sources: Cnbx Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cnbx Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cnbx Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| InMed Pharmaceuticals Inc | Named by the company | 85% |
| GW Pharmaceuticals PLC | Named by the company | 85% |
| Zynerba Pharmaceuticals Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Cure Pharmaceutical Holding Corp | Named by the company | 85% |
| Emerald Bioscience Inc | Named by the company | 85% |
| Cannabis Science Inc | Named by the company | 85% |
| Tetra Bio-Pharma Inc | Named by the company | 85% |
| Pharmacyte Biotech Inc | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cnbx Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cnbx Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Novabridge Biosciences | Oncology 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cnbx Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cnbx Pharmaceuticals Inc | - | 270,120 | -231,063 |
| Corbus Pharmaceuticals Holdings Inc | 132 | 42,775 | -2,830,639 |
| Novabridge Biosciences | 131 | - | - |
| Inmed Pharmaceuticals Inc | 6 | 1,161,264 | -2,165,409 |
| Pharmacyte Biotech Inc | 4 | - | -8,170,423 |
| PEERS TOTAL | 273 | 193,352 | -4,034,211 |
Cnbx Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -25.62 % | - | - | - | - | - | - |
| Operating Margin | -35,163.86 % | -22,183.56 % | - | - | - | - | - | - |
| Return on Invested Capital | -44.54 % | -6.34 % | -80.20 % | -77.88 % | 80.57 % | 18.83 % | 9.14 % | 5.87 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cnbx Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (66.70 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cnbx Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cnbx Pharmaceuticals Inc | 0.00 | 0.01 | - |
| Corbus Pharmaceuticals Holdings Inc | 1.35 | 6.99 | - |
| Novabridge Biosciences | 7.83 | 8.09 | - |
| Inmed Pharmaceuticals Inc | 3.64 | 4.40 | 0.01 |
| Pharmacyte Biotech Inc | 10.99 | 18.70 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cnbx Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cnbx Pharmaceuticals Inc | Q2 2026 | - | - |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
| Novabridge Biosciences | Q4 2025 | - | - |
| Inmed Pharmaceuticals Inc | Q2 2026 | - | - |
| Pharmacyte Biotech Inc | Q2 2026 | - | - |
| PEERS TOTAL | - | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cnbx Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cnbx Pharmaceuticals Inc | Q2 2026 | - | - |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
| Novabridge Biosciences | Q4 2025 | - | -85.4 % |
| Inmed Pharmaceuticals Inc | Q2 2026 | - | - |
| Pharmacyte Biotech Inc | Q2 2026 | - | - |
Cnbx Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cnbx Pharmaceuticals Inc | - | - | - |
| Corbus Pharmaceuticals Holdings Inc | - | - | - |
| Novabridge Biosciences | - | - | - |
| Inmed Pharmaceuticals Inc | - | - | - |
| Pharmacyte Biotech Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cnbx Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cnbx Pharmaceuticals Inc | - | - |
| Corbus Pharmaceuticals Holdings Inc | - | 85.95 |
| Novabridge Biosciences | - | - |
| Inmed Pharmaceuticals Inc | - | 0.81 |
| Pharmacyte Biotech Inc | - | - |
| PEERS AVERAGE | - | 30.19 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.